KRAS and non-small cell lung carcinoma: Recently, the phase 3 multicenter CodeBreak 200 clinical trial (NCT04303780) of a type of combined treatment using sotorasib and docetaxel has been used for patients with locally progressive and unresectable or metastatic NSCLC with KRAS G12C mutations [37–40].